Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety

BACKGROUND: Anakinra is the first interleukin-1 inhibitor to be used in clinical practice, and recent evidence showed that interleukin-1 plays a pivotal role in the pathogenesis of adult-onset Still disease (AoSD). However, data concerning efficacy with anakinra use in different clinical trials has...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Dongsheng, Yang, Zhihai, Han, Shuyin, Liang, Xingguang, Ma, Kuifen, Zhang, Xingguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251663/
https://www.ncbi.nlm.nih.gov/pubmed/25473268
http://dx.doi.org/10.2147/DDDT.S73428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251663/
https://www.ncbi.nlm.nih.gov/pubmed/25473268
http://dx.doi.org/10.2147/DDDT.S73428

Ejemplares similares